

Real-life effectiveness of narrowband UVB phototherapy for pityriasis lichenoides

Rachele Bardelli,^{1,2} Francesco Bellinato,¹ Andrea Carugno,^{2,3} Nicola Zerbinati,^{2,4} Paolo Gisondi,¹ Giampiero Girolomoni¹

¹Section of Dermatology and Venereology, Department of Medicine, University of Verona; ²Dermatology Unit, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese; ³Department of Medicine and Surgery, University of Insubria, Varese; ⁴Department of Medicine and Innovation Technology, University of Insubria, Varese, Italy

Dear Editor,

Pityriasis lichenoides (PL) is an inflammatory skin disease of unknown etiology. The clinical spectrum of pityriasis lichenoides encompasses febrile ulcer-necrotic Mucha-Habermann disease (FUMHD), pityriasis lichenoides et varioliformis acuta (PLEVA), and pityriasis lichenoides chronica (PLC).¹ Phototherapy is an

effective and well-tolerated modality that is often successful for persistent PL or resistant to topical treatments.² A retrospective observational study was conducted involving patients from the dermatology section of the University of Verona with a confirmed histological diagnosis of PLEVA and PLC accessed between January 2003 and June 2024. Of these, only those undergoing narrowband-ultraviolet-B (NB-UVB) phototherapy were selected, considering both children and adults. NB-UVB phototherapy was administered using a UV70001 cabin (Waldmann-Lichttechnik). According to the standardized phototherapy protocol, patients initially received 70% of the minimum erythema dose. Subsequent doses of NB-UVB were increased by 10-20% compared to the previous session, based on clinical response, with a maximum of 60 sessions. Dose increments were withheld in cases of moderate or persistent erythema. Upon resolution of the lesions, treatment was continued for at least three weeks without increasing the dose. NB-UVB treatment frequency (two or three times weekly) was tailored to disease severity. Patients were observed for approximately one year after discontinuation of therapy. Data were retrospectively retrieved from electronic medical records. Baseline demographic characteristics and potential triggers were recorded. The primary endpoint was defined as achieving complete remission (>90% body surface area clearance). Secondary endpoints included relapse rate and time to relapse, comparing PLEVA vs. PLC. Time to relapse was calculated from complete remission until the onset of new clinically objective lesions. The recurrence rate was determined based on the proportion of patients experiencing lesion recurrence following complete remission.

A total of 39 patients were included; 21 (53.8%) were male, with a mean age of 31.1 ± 23.4 years. Among them, 28 (71.8%) patients had PLC and 11 (28.2%) had PLEVA. A triggering event was reported in 10 (25.6%) patients one month before the onset of the disease, in particular: 3 (30.0%) experienced respiratory tract infection; 3 (30.0%) had unspecified febrile episodes; and 4 (40.0%) had vaccination, including one each for SARS-CoV-2, tetanus, and influenza. Patients achieving complete remission accounted for 30 (77.0%) cases. Complete remission was similar in patients with PLEVA, 9/11 (81.8%), compared to those with PLC, 21/28 (75.0%) ($p=0.65$). The mean cumulative NB-UVB dose required to achieve complete remission was 26.7 ± 24.9 J/cm². In particular, 22.7 ± 20.1 J/cm² for PLC and 36.2 ± 34.1 J/cm² for PLEVA ($p=0.18$) (Table 1). Three (7.6%) phototype II patients reported minimal erythema, and none discontinued treatment due to side effects.

Relapse occurred in 14 (35.9%) patients. Relapse rates were similar in PLC and PLEVA, occurring in 4 (36.3%) patients with PLEVA and 10 (35.7%) with PLC ($p=0.97$). Lesions demonstrated a median time to recurrence of 4.6 ± 2.2 months: specifically, 4.0 ± 2.2 months in PLEVA and 5.3 ± 2.5 months in PLC ($p=0.37$) (Table 2).

In this study, we assessed the effectiveness of NB-UVB pho-

Correspondence: Francesco Bellinato, MD, Section of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale A. Stefani 1, 37126 Verona, Italy.

E-mail: francesco.bellinato@univr.it

Tel.: + 39 0458122547

Key words: pityriasis lichenoides; phototherapy; narrowband UVB.

Contributions: FB, conceptualization; FB, RB, formal analysis; RB, resources, software; RB, FB, writing – original draft; RB, FB, GG, PG, AC, NZ, writing - review and editing. All authors have read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Conflict of interest: the authors have no conflict of interest to declare.

Ethics approval and consent to participate: the study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the ethics committees of the participating institutions [protocol number 1483]. Informed consent was obtained from all participants included in this study.

Availability of data and materials: the data that support the findings of this study are available from the corresponding author upon reasonable request.

Received: 30 January 2025.

Accepted: 22 October 2025.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2025

Licensee PAGEPress, Italy

Dermatology Reports 2025; 17:10272

doi:10.4081/dr.2025.10272

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Table 1. Clinical response and phototherapeutic doses of the patients.

	PLEVA (n=11)	PLC (n=28)	Total (n=39)	p
Complete response, n (%)	9 (81.8%)	21 (75.0%)	30 (77.0%)	0.65
Mean cumulative dose, J/cm ² ±SD	36.2±34.1	22.7±20.1	26.7±24.9	0.18

PLEVA, pityriasis lichenoides et varioliformis acuta; PLC, pityriasis lichenoides chronica; SD, standard deviation.

Table 2. Relapses and recurrences in patients with pityriasis lichenoides.

	PLEVA	PLC	Total	p
Relapses, n (%)	4 (36.3%)	10 (35.7%)	14 (35.9%)	0.97
Median recurrence, months±SD	4.0±2.2	5.3±2.5	4.6±2.2	0.37

PLEVA, pityriasis lichenoides et varioliformis acuta; PLC, pityriasis lichenoides chronica; SD, standard deviation.

totherapy in PL patients. The rate of complete remission was similar between patients with PLEVA and those with PLC, with comparable cumulative doses of NB-UVB between the two groups. Psoralen plus ultraviolet A (PUVA) and ultraviolet A (UVA) phototherapy appear to be equally effective as NB-UVB. NB-UVB phototherapy is indicated as an effective and first-line treatment for PL patients, both adults and children.³ Methotrexate and antibiotics like tetracyclines and macrolides are alternative drugs when phototherapy is not effective or feasible.

Other systemic therapies, such as dapsone, systemic glucocorticoids, and intravenous immunoglobulin, have been suggested for the treatment of refractory PLEVA or FUMHD based on isolated case reports.³ A study by Agaoglu *et al.*⁴ reported that 6 of 8 (75.0%) patients with PLEVA led to complete remission with a mean cumulative dose of 40.1 J/cm², and 8 of 12 (66.7%) with PLC had complete remission with a mean cumulative dose of 95.0 J/cm².

The complete remission data are similar to our study, either in PLEVA (75.0% vs. 81.8%) and PLC (66.7% vs. 75%). The mean cumulative dose instead was lower (36.2 J/cm² vs. 40.1 J/cm² for PLEVA and 22.7 J/cm² vs. 95.0 J/cm² for PLC). This difference in cumulative dose may be due to different disease severity and demographic characteristics. Regarding recurrences, relapses occurred in 14 patients (35.9%) in our cohort. Some studies showed 42-73% relapse-free rates after NB-UVB, with a mean follow-up duration of 9-34 months.⁵ Our patients were followed up for a shorter period, and this could explain why fewer relapses

were identified (35.9%). One of the main limitations of this study is its retrospective design and the lack of follow-up for more than 12 months. Indeed, recurrences of PL have been reported even after years.⁵

In conclusion, NB-UVB phototherapy is an effective and safe treatment option for patients with PL and should be considered a first-line therapy. However, further studies are required to establish a maintenance schedule in patients with recurrent disease.

References

1. Bowers S, Warshaw EM. Pityriasis lichenoides and its subtypes. *J Am Acad Dermatol* 2006;55:557-72.
2. Brazzelli V, Carugno A, Rivetti N, et al. Narrowband UVB phototherapy for pediatric generalized pityriasis lichenoides. *Photodermatol Photoimmunol Photomed* 2013;29:330-3.
3. Bellinato F, Maurelli M, Gisondi P, Girolomoni G. A systematic review of treatments for pityriasis lichenoides. *J Eur Acad Dermatol Venereol* 2019;33:2039-49.
4. Agaoglu E, Erdogan HK, Acer E, et al. Narrowband ultraviolet B phototherapy for pityriasis lichenoides: A real-life experience. *Photodermatol Photoimmunol Photomed* 2023;39:520-6.
5. Ersoy-Evans S, Hapa AA, Boztepe G, et al. Narrowband ultraviolet-B phototherapy in pityriasis lichenoides chronica. *J Dermatolog Treat* 2009;20:109-13.